FOLH1 and prostate cancer: As a different PSMA localization (tumor cell surface in prostate cancer versus neovasculature in other solid cancers) might lead to different PSMA tracer kinetics, preferably these prospective studies should include multi-timepoint post-therapy imaging (dosimetry), to provide more information on PSMA tracer kinetics.